Minerva Neurosciences (NERV) Share-based Compensation (2014 - 2026)
Minerva Neurosciences (NERV) posted Share-based Compensation of $8.7 million for Q1 2026, up 1797.55% on a QoQ basis from $459028.0 in Q4 2025, and up 2830.5% year-over-year from $297229.0 in Q1 2025.
Minerva Neurosciences (NERV) Share-based Compensation (2014 - 2026) Analysis & Trends
Minerva Neurosciences' Share-based Compensation history runs 13 years deep, the most recent figure standing at $8.7 million for Q1 2026.
- Quarterly Share-based Compensation rose 2830.5% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.8 million (up 724.79% YoY) and the FY2025 annual result came in at $25.0 million, up 792.86% from the prior year.
- Share-based Compensation was $8.7 million for Q1 2026 at Minerva Neurosciences, up from $459028.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $8.7 million in Q1 2026 and bottomed at $249650.0 in Q4 2024.
- A 5-year average of $1.1 million and a median of $459028.0 in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation sank 64.24% — and 2026, when it jumped 2830.5%.
- Minerva Neurosciences' Share-based Compensation stood at $947684.0 in 2022, then slumped by 35.52% to $611064.0 in 2023, then slumped by 59.15% to $249650.0 in 2024, then surged by 83.87% to $459028.0 in 2025, then soared by 1797.55% to $8.7 million in 2026.
- Business Quant data shows NERV's Share-based Compensation at $8.7 million in Q1 2026, $459028.0 in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | 8.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.71 Mn |
| Mar 31, 2026 | 8.71 Mn |
| Dec 31, 2025 | 459,028.00 |
| Dec 31, 2025 | 459,028.00 |
| Sep 30, 2025 | 1.80 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 298,218.00 |
| Jun 30, 2025 | 298,218.00 |
| Mar 31, 2025 | 297,229.00 |
| Mar 31, 2025 | 297,229.00 |
| Dec 31, 2024 | 249,650.00 |
| Dec 31, 2024 | 249,650.00 |
| Sep 30, 2024 | 307,708.00 |
| Sep 30, 2024 | 307,708.00 |
| Jun 30, 2024 | 329,318.00 |
| Jun 30, 2024 | 329,318.00 |
| Mar 31, 2024 | 438,849.00 |
| Mar 31, 2024 | 438,849.00 |
| Dec 31, 2023 | 611,064.00 |
| Dec 31, 2023 | 611,064.00 |